Insider transactions

EDGAR

Whitehawk Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
14 transactions, 705,358 shares
Sum of shares × price per share: 2,584,560.1888

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 70

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-09-15 Filed 2026-09-18Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (193,957) — exercise price 4.09
Acquired (A)193,9570—193,957Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001995275-26-000018 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-18Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (193,957)
Acquired (A)193,9570—193,957Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  • F3 The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001995275-26-000018 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-18Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (118,476) — exercise price 4.09
Acquired (A)118,4760—118,476Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001754154-26-000016 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-18Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (118,476)
Acquired (A)118,4760—118,476Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  • F3 The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001754154-26-000016 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-18BALL BRYAN Officer: See remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (91,633) — exercise price 4.09
Acquired (A)91,6330—91,633Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001766522-26-000017 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-18BALL BRYAN Officer: See remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (91,633)
Acquired (A)91,6330—91,633Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  • F3 The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001766522-26-000017 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-18Dornan David Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (85,887) — exercise price 4.09
Acquired (A)85,8870—85,887Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001821353-26-000007 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-18Dornan David Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (85,887)
Acquired (A)85,8870—85,887Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  • F3 The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001821353-26-000007 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-18Dugan Margaret Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (81,250) — exercise price 4.09
Acquired (A)81,2500—81,250Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001909734-26-000011 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-18Dugan Margaret Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (81,250)
Acquired (A)81,2500—81,250Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  • F3 The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001909734-26-000011 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-15Dugan Margaret Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (81,250) — exercise price 4.09
Acquired (A)81,2500—81,250Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001909734-26-000009 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-15Dugan Margaret Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (81,250)
Acquired (A)81,2500—81,250Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  • F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001909734-26-000009 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-15Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock option (right to buy) — underlying Common Stock (193,957) — exercise price 4.09
Acquired (A)193,9570—193,957Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001995275-26-000016 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-15Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (193,957)
Acquired (A)193,9570—193,957Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  • F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001995275-26-000016 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-15Dornan David Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (85,887) — exercise price 4.09
Acquired (A)85,8870—85,887Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001821353-26-000005 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-15Dornan David Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (85,887)
Acquired (A)85,8870—85,887Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  • F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001821353-26-000005 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-15Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (118,476) — exercise price 4.09
Acquired (A)118,4760—118,476Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001754154-26-000014 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-15Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (118,476)
Acquired (A)118,4760—118,476Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  • F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001754154-26-000014 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-15BALL BRYAN Officer: See remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (91,633) — exercise price 4.09
Acquired (A)91,6330—91,633Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001766522-26-000015 Read from the filing’s XML Dispute this row
2026-09-15 Filed 2026-09-15BALL BRYAN Officer: See remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (91,633)
Acquired (A)91,6330—91,633Direct (D) No
F2, F3
  • F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
  • F3 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date, and twenty five percent (25%) of the shares subject to the award shall vest on each of the next three Vesting Commencement Date anniversaries thereafter. Vesting Commencement Date shall mean September 15, 2026.
Open filing 0001766522-26-000015 Read from the filing’s XML Dispute this row
2026-09-09 Filed 2026-09-11Iyengar Vijay K Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (76,080) — exercise price 4.19
Acquired (A)76,0800—76,080Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month) such that all shares subject to the option shall be fully vested on the three year anniversary of the grant date. The grant date is September 9, 2026.
Open filing 0001670000-26-000008 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-07-30Dalal Anupam Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,040) — exercise price 4.16
Acquired (A)38,0400—38,040Direct (D) No
F2
  • F2 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. Date of Grant shall mean June 12, 2026.
Open filing 0001602474-26-000004 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-15Maroun Richard E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,040) — exercise price 4.16
Acquired (A)38,0400—38,040Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. Date of Grant shall mean June 12, 2026.
Open filing 0001364590-26-000003 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-15Castelein Caley Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,040) — exercise price 4.16
Acquired (A)38,0400—38,040Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. Date of Grant shall mean June 12, 2026.
Open filing 0001355758-26-000007 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-15Hirmand Mohammad Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,040) — exercise price 4.16
Acquired (A)38,0400—38,040Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. Date of Grant shall mean June 12, 2026.
Open filing 0001654482-26-000003 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-15Aghazadeh Behzad Director · 10% owner · Other: See remarksAvoro Capital Advisors LLC Director · 10% owner · Other: See remarksAvoro Ventures LLC Director · 10% owner · Other: See remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,040) — exercise price 4.16
Acquired (A)38,0400—38,040Direct (D) No
F1, F2, F3
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. Date of Grant shall mean June 12, 2026.
  • F2 This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (Avoro Capital Advisors), Avoro Ventures LLC, a Delaware limited liability company (Avoro Ventures) and Behzad Aghazadeh (Dr. Aghazadeh, and together with Avoro Capital Advisors and Avoro Ventures, the Reporting Persons). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.
  • F3 The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Open filing 0001701815-26-000006 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-15Zhao Baiteng Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,040) — exercise price 4.16
Acquired (A)38,0400—38,040Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. Date of Grant shall mean June 12, 2026.
Open filing 0002049287-26-000003 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-15Desai Neil Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,040) — exercise price 4.16
Acquired (A)38,0400—38,040Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. Date of Grant shall mean June 12, 2026.
Open filing 0001878692-26-000003 Read from the filing’s XML Dispute this row
2026-06-12 Filed 2026-06-15Reeve Emma Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (38,040) — exercise price 4.16
Acquired (A)38,0400—38,040Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. Date of Grant shall mean June 12, 2026.
Open filing 0001680329-26-000005 Read from the filing’s XML Dispute this row
2026-05-14 Filed 2026-07-30Dalal Anupam Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,275,5103.92
4,999,999.2

Derived: shares × price per share. Exact value 4999999.20.

4,685,912Indirect (I) See footnoteNo
F1
  • F1 Consists of (i) 3,538,288 shares held by Acuta Capital Fund, LP (Acuta Capital) and (ii) 1,147,624 shares held by Acuta Opportunity Fund, LP. (Acuta Opportunity Fund). Acuta Capital Partners, LLC (Acuta Partners) is the general partner of each of Acuta Capital and Acuta Opportunity Fund. The Reporting Person is the Chief Investment Officer and Managing Member of Acuta Partners. The Reporting Person has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and the Reporting Person disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein.
Open filing 0001602474-26-000004 Read from the filing’s XML Dispute this row
2026-05-14 Filed 2026-05-18Castelein Caley Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)255,1023.92
999,999.84

Derived: shares × price per share. Exact value 999999.84.

274,796Direct (D) No— Open filing 0001355758-26-000003 Read from the filing’s XML Dispute this row
2026-05-14 Filed 2026-05-18Castelein Caley Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Pre-Funded Warrant (right to buy) — underlying Common Stock (2,072,756) — exercise price .0001
Acquired (A)2,072,7568,124,996.24
16,841,134,706,437.44

Derived: shares × price per share. Exact value 16841134706437.44.

2,072,756Indirect (I) See footnoteNo
F2, F3
  • F2 Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 14, 2026, exercise the Pre-Funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the holder cannot exercise any of the Pre-Funded Warrant to the extent the holder and its affiliates, including the Reporting Person, would beneficially own, after any such exercise, more than 4.99% of the outstanding Common Stock.
  • F3 Pre-Funded Warrant held by KVP Capital, LP. The Reporting Person is the Managing Director of KVP Capital. The Reporting Person disclaims beneficial ownership of the Pre-Funded Warrant held by KVP Capital, except to the extent of his pecuniary interest therein.
Open filing 0001355758-26-000003 Read from the filing’s XML Dispute this row
2026-05-14 Filed 2026-05-18BALL BRYAN Officer: See remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)51,0203.92
199,998.4

Derived: shares × price per share. Exact value 199998.40.

448,126Direct (D) No— Open filing 0001766522-26-000013 Read from the filing’s XML Dispute this row
2026-05-14 Filed 2026-05-18Dugan Margaret Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)19,1323.92
74,997.44

Derived: shares × price per share. Exact value 74997.44.

19,132Direct (D) No— Open filing 0001909734-26-000005 Read from the filing’s XML Dispute this row
2026-05-14 Filed 2026-05-18Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)51,0213.92
200,002.32

Derived: shares × price per share. Exact value 200002.32.

569,643Direct (D) No— Open filing 0001995275-26-000014 Read from the filing’s XML Dispute this row
2026-05-14 Filed 2026-05-18Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)38,2653.92
149,998.8

Derived: shares × price per share. Exact value 149998.80.

333,489Direct (D) No— Open filing 0001754154-26-000012 Read from the filing’s XML Dispute this row
2026-05-12 Filed 2026-05-14Avoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · 10% owner · Other: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Pre-funded Warrant (right to buy) — underlying Common Stock (6,377,714) — exercise price 0.0001
Acquired (A)6,377,7143.9199
25,000,001.1086

Derived: shares × price per share. Exact value 25000001.1086.

14,710,714Indirect (I) See footnotesNo
F1, F2, F3, F4
  • F1 The securities reported herein were acquired on behalf of accounts managed by Avoro Capital Advisors (as defined below) directly from the Issuer in a private placement.
  • F2 Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after May 12, 2026, exercise the Pre-funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the Reporting Persons cannot exercise any of the Pre-Funded Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 19.99% of the outstanding Common Stock (the 19.99% Blocker). Consequently, at this time, the Reporting Persons are not able to exercise all the Pre-Funded Warrants due to the 19.99% Blocker.
  • F3 This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company (Avoro Capital Advisors), Avoro Ventures LLC, a Delaware limited liability company (Avoro Ventures) and Behzad Aghazadeh (Dr. Aghazadeh, and together with Avoro Capital Advisors and Avoro Ventures, the Reporting Persons). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures.
  • F4 The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.
Open filing 0000902664-26-002449 Read from the filing’s XML Dispute this row
2026-04-16 Filed 2026-04-17Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)141,6004.13
584,808

Derived: shares × price per share. Exact value 584808.00.

295,224Direct (D) No
F1
  • F1 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001754154-26-000010 Read from the filing’s XML Dispute this row
2026-04-15 Filed 2026-04-17Giacobello Scott M. Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)77,0003.86
297,220

Derived: shares × price per share. Exact value 297220.00.

436,824Direct (D) No
F1, F2
  • F1 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
  • F2 Includes an aggregate of 11,822 shares of Common Stock acquired between November 14, 2022 and November 15, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
Open filing 0001754154-26-000010 Read from the filing’s XML Dispute this row
2026-04-14 Filed 2026-04-15BALL BRYAN Officer: See remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)92,4603.64
336,554.4

Derived: shares × price per share. Exact value 336554.40.

397,106Direct (D) No
F1
  • F1 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001766522-26-000011 Read from the filing’s XML Dispute this row
2026-04-13 Filed 2026-04-15BALL BRYAN Officer: See remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)26,3893.46
91,305.94

Derived: shares × price per share. Exact value 91305.94.

489,566Direct (D) No
F1
  • F1 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001766522-26-000011 Read from the filing’s XML Dispute this row
2026-04-10 Filed 2026-04-13BALL BRYAN Officer: See remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,5963.43
22,624.28

Derived: shares × price per share. Exact value 22624.28.

515,955Direct (D) No
F1
  • F1 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001766522-26-000009 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-13BALL BRYAN Officer: See remarks
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)50,0003.57
178,500

Derived: shares × price per share. Exact value 178500.00.

522,551Direct (D) No
F1
  • F1 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001766522-26-000009 Read from the filing’s XML Dispute this row
2026-04-09 Filed 2026-04-10Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)14,5003.38
49,010

Derived: shares × price per share. Exact value 49010.00.

518,622Direct (D) No
F1
  • F1 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001995275-26-000012 Read from the filing’s XML Dispute this row
2026-04-08 Filed 2026-04-08Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)63,9453.4
217,413

Derived: shares × price per share. Exact value 217413.0.

533,122Direct (D) No
F1
  • F1 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001995275-26-000008 Read from the filing’s XML Dispute this row
2026-04-07 Filed 2026-04-08Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)94,0873.43
322,718.41

Derived: shares × price per share. Exact value 322718.41.

597,067Direct (D) No
F1
  • F1 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001995275-26-000008 Read from the filing’s XML Dispute this row
2026-04-06 Filed 2026-04-08Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)102,3953.51
359,406.45

Derived: shares × price per share. Exact value 359406.45.

691,154Direct (D) No
F1
  • F1 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001995275-26-000008 Read from the filing’s XML Dispute this row
2026-04-02 Filed 2026-04-03Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)26,8583.48
93,465.84

Derived: shares × price per share. Exact value 93465.84.

793,549Direct (D) No
F2
  • F2 Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Open filing 0001995275-26-000006 Read from the filing’s XML Dispute this row
2026-04-01 Filed 2026-04-03Dugan Margaret Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (283,157) — exercise price 3.54
Acquired (A)283,1570—283,157Direct (D) No
F1
  • F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Vesting Commencement Date shall mean April 1, 2026.
Open filing 0001909734-26-000003 Read from the filing’s XML Dispute this row
2026-04-01 Filed 2026-04-03Lennon David James Director · Officer: CHIEF EXECUTIVE OFFICER
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)775,828——820,407Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
Open filing 0001995275-26-000006 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-18. Prior quarter ending 2026-06-30: 9,170 filings read.

Showing 1–50 of 92

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Yu Fan 4,829,398 SH18,158,536 dollarsLower by 31,916 Prior quarter: 4,861,314Open filing 0001193125-26-463618 Filed 2026-11-16 Dispute this row
ACUTA CAPITAL PARTNERS, LLC 4,685,912 SH17,619,029 dollarsUnchanged Prior quarter: 4,685,912Open filing 0001104659-26-127905 Filed 2026-11-16 Dispute this row
QVT Financial LP 4,615,709 SH15,619,559 dollarsUnchanged Prior quarter: 4,615,709Open filing 0001193125-26-463263 Filed 2026-11-16 Dispute this row
MONTANOVA CAPITAL, LLC 4,170,875 SH15,682,490 dollarsLower by 129,125 Prior quarter: 4,300,000Open filing 0001172661-26-005325 Filed 2026-11-16 Dispute this row
ORBIMED ADVISORS LLC 3,853,472 SH14,489,055 dollarsLower by 80,824 Prior quarter: 3,934,296Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row
Avoro Capital Advisors LLC 2,849,402 SH10,713,752 dollarsUnchanged Prior quarter: 2,849,402Open filing 0001104659-26-127608 Filed 2026-11-16 Dispute this row
BlackRock, Inc. Partly reported under another manager2,589,723 SH9,737,359 dollarsHigher by 666,895 Prior quarter: 1,922,828Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Siren, L.L.C. Partly reported under another manager2,337,102 SH8,787,504 dollarsUnchanged Prior quarter: 2,337,102Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row
KVP Capital Advisors, LP 2,165,997 SH8,144,149 dollarsUnchanged Prior quarter: 2,165,997Open filing 0001104659-26-127594 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,465,827 SH5,511,510 dollarsHigher by 77,266 Prior quarter: 1,388,561Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
ADAR1 Capital Management, LLC 1,341,394 SH5,043,641 dollarsUnchanged Prior quarter: 1,341,394Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager1,055,562 SH3,969,690 dollarsHigher by 155,782 Prior quarter: 899,780Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
ACORN CAPITAL ADVISORS, LLC 932,139 SH3,504,843 dollarsLower by 207,224 Prior quarter: 1,139,363Open filing 0001636587-26-000102 Filed 2026-11-16 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager663,922 SH2,496,347 dollarsHigher by 250,100 Prior quarter: 413,822Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
STATE STREET CORP Partly reported under another manager591,672 SH2,224,687 dollarsHigher by 204,690 Prior quarter: 386,982Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
TWO SIGMA INVESTMENTS, LP 550,739 SH2,070,779 dollarsHigher by 254,127 Prior quarter: 296,612Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
Woodline Partners LP 507,061 SH1,906,549 dollarsHigher by 70,447 Prior quarter: 436,614Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
STEMPOINT CAPITAL LP 495,980 SH1,864,885 dollarsLower by 525,057 Prior quarter: 1,021,037Open filing 0001420506-26-002774 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 442,900 SH1,665,304 dollarsHigher by 62,494 Prior quarter: 380,406Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager436,226 SH1,635 dollarsHigher by 265,343 Prior quarter: 170,883Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager329,303 SH1,238,179 dollarsHigher by 64,614 Prior quarter: 264,689Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
Eversept Partners, LP 303,171 SH1,139,923 dollarsLower by 135 Prior quarter: 303,306Open filing 0001697013-26-000007 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 296,030 SH1,113,073 dollarsHigher by 76,813 Prior quarter: 219,217Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 283,605 SH1,066,355 dollarsHigher by 36,698 Prior quarter: 246,907Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Squarepoint Ops LLC Partly reported under another manager206,513 SH776,489 dollarsNot in the prior quarter’s filings read Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row
Qube Research Technologies Ltd 197,064 SH740,961 dollarsHigher by 148,071 Prior quarter: 48,993Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager196,509 SH738,874 dollarsHigher by 69,751 Prior quarter: 126,758Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
Verdad Advisers, LP 153,698 SH577,904 dollarsLower by 147,785 Prior quarter: 301,483Open filing 0001420506-26-002833 Filed 2026-11-16 Dispute this row
BRIDGEWAY CAPITAL MANAGEMENT, LLC 115,284 SH433,468 dollarsLower by 50,000 Prior quarter: 165,284Open filing 0001107261-26-000007 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 105,867 SH398,060 dollarsHigher by 27,035 Prior quarter: 78,832Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager105,011 SH394,682 dollarsHigher by 71,591 Prior quarter: 33,420Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager98,416 SH370,044 dollarsHigher by 15,784 Prior quarter: 82,632Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
UBS Group AG Partly reported under another manager78,502 SH295,167 dollarsHigher by 27,661 Prior quarter: 50,841Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Integrated Quantitative Investments LLC 75,846 SH285,181 dollarsNot in the prior quarter’s filings read Open filing 0001941040-26-000818 Filed 2026-11-13 Dispute this row
Jump Financial, LLC Partly reported under another manager71,400 SH268,464 dollarsHigher by 30,600 Prior quarter: 40,800Open filing 0000905148-26-004786 Filed 2026-11-13 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager63,973 SH240,538 dollarsHigher by 12,133 Prior quarter: 51,840Open filing 0000748054-26-000008 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager63,133 SH237,380 dollarsHigher by 33,153 Prior quarter: 29,980Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Nuveen, LLC Partly reported under another manager54,530 SH205,033 dollarsHigher by 10,731 Prior quarter: 43,799Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
FMR LLC Partly reported under another manager43,933 SH165,188 dollarsHigher by 43,763 Prior quarter: 170Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Invesco Ltd. Partly reported under another manager43,888 SH165,020 dollarsHigher by 4,709 Prior quarter: 39,179Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
HRT FINANCIAL LP 43,614 SH163 dollarsNot in the prior quarter’s filings read Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager36,657 SH137,830 dollarsHigher by 4,989 Prior quarter: 31,668Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager35,726 SH134,330 dollarsHigher by 1,100 Prior quarter: 34,626Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
XTX Topco Ltd Partly reported under another manager35,666 SH134,104 dollarsHigher by 17,144 Prior quarter: 18,522Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row
Susquehanna Portfolio Strategies, LLC 29,148 SH109,596 dollarsNot in the prior quarter’s filings read Open filing 0001996449-26-000009 Filed 2026-11-16 Dispute this row
LOS ANGELES CAPITAL MANAGEMENT LLC 28,380 SH106,709 dollarsNot in the prior quarter’s filings read Open filing 0001177206-26-000010 Filed 2026-11-12 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager26,609 SH101 dollarsUnchanged Prior quarter: 26,609Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
MetLife Investment Management, LLC Partly reported under another manager25,768 SH96,888 dollarsNot in the prior quarter’s filings read Open filing 0001628280-26-073956 Filed 2026-11-16 Dispute this row
RHUMBLINE ADVISERS 25,108 SH94,404 dollarsHigher by 579 Prior quarter: 24,529Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
Empirical Financial Services, LLC d.b.a. Empirical Wealth Management 22,913 SH86,153 dollarsNot in the prior quarter’s filings read Open filing 0001085146-26-000916 Filed 2026-10-27 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Ally Bridge Group (NY) LLC 817,939 SH
  • Balyasny Asset Management L.P. 288,117 SH
  • Sixth Street Partners Management Company, L.P. 78,832 SH
  • Y-Intercept (Hong Kong) Ltd 24,363 SH
  • Virtu Financial LLC 14,479 SH
  • Scientech Research LLC 10,838 SH
  • Quadrature Capital Ltd 10,044 SH
  • TWO SIGMA SECURITIES, LLC 10,033 SH
  • Quarry LP 218 SH
  • Integrated Wealth Concepts LLC 132 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Dellora Investments LP Common Stock, $0.0001 par value per share5.63,169,287.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001943462-26-000010 Dispute this row
Kevin Pyun Common Stock, $0.0001 par value per share5.63,169,287.0009/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001943462-26-000010 Dispute this row
ABG Management Ltd. Common Stock, par value $0.0001 per share00.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-052436 Dispute this row
Ally Bridge Group (NY) LLC Common Stock, par value $0.0001 per share00.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-052436 Dispute this row
Ally Bridge MedAlpha Master Fund L.P. Common Stock, par value $0.0001 per share00.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-052436 Dispute this row
ABG Global Life Science Capital Partners V GP Limited Common Stock, par value $0.0001 per share7.84,829,398.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-052436 Dispute this row
ABG Global Life Science Capital Partners V GP, L.P. Common Stock, par value $0.0001 per share7.84,829,398.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-052436 Dispute this row
Ally Bridge Group Global Life Science Capital Partners V, L.P. Common Stock, par value $0.0001 per share7.84,829,398.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-052436 Dispute this row
ABG-SIV, L.P. Common Stock, par value $0.0001 per share7.84,829,398.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-052436 Dispute this row
ABG V-SIV Limited Common Stock, par value $0.0001 per share7.84,829,398.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-052436 Dispute this row
Fan Yu Common Stock, par value $0.0001 per share7.84,829,398.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001493152-26-052436 Dispute this row
Coastlands Capital LP Common Stock, par value $0.0001 per share6.193,653,440.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127421 Dispute this row
Coastlands Capital Partners LP Common Stock, par value $0.0001 per share6.193,653,440.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127421 Dispute this row
Coastlands Capital GP LLC Common Stock, par value $0.0001 per share6.193,653,440.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127421 Dispute this row
Coastlands Capital LLC Common Stock, par value $0.0001 per share6.193,653,440.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127421 Dispute this row
Matthew D. Perry Common Stock, par value $0.0001 per share6.193,653,440.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-127421 Dispute this row
OrbiMed Advisors LLC Common Stock, par value $0.0001 per share7.33,934,296.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0000947871-26-000805 Dispute this row
OrbiMed Genesis GP LLC Common Stock, par value $0.0001 per share7.33,934,296.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0000947871-26-000805 Dispute this row
ABG Management Ltd. Common Stock, par value $0.0001 per share1.4817,939.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
Ally Bridge Group (NY) LLC Common Stock, par value $0.0001 per share1.4817,939.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
Ally Bridge MedAlpha Master Fund L.P. Common Stock, par value $0.0001 per share1.4817,939.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
ABG Innovation Capital Partners III GP Limited Common Stock, par value $0.0001 per share00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
ABG Innovation Capital Partners III GP, L.P. Common Stock, par value $0.0001 per share00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
Ally Bridge Group Innovation Capital Partners III, L.P. Common Stock, par value $0.0001 per share00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
ABG Innovation-SO Limited Common Stock, par value $0.0001 per share00.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
ABG Global Life Science Capital Partners V GP Limited Common Stock, par value $0.0001 per share8.14,861,314.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
ABG Global Life Science Capital Partners V GP, L.P. Common Stock, par value $0.0001 per share8.14,861,314.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
Ally Bridge Group Global Life Science Capital Partners V, L.P. Common Stock, par value $0.0001 per share8.14,861,314.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
ABG-SIV, L.P. Common Stock, par value $0.0001 per share8.14,861,314.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
ABG V-SIV Limited Common Stock, par value $0.0001 per share8.14,861,314.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
Fan Yu Common Stock, par value $0.0001 per share9.45,679,253.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-038432 Dispute this row
ACUTA CAPITAL PARTNERS, LLC Common Stock8.74,685,912.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 2Open filing 0000935836-26-000289 Dispute this row
ANUPAM DALAL Common Stock9.04,843,775.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 2Open filing 0000935836-26-000289 Dispute this row
Acuta Capital Fund, LP Common Stock6.63,538,288.0005/14/2026 Filed 2026-05-18SCHEDULE 13D/AAmendment 2Open filing 0000935836-26-000289 Dispute this row
Avoro Capital Advisors LLC Common stock, par value $0.0001 per share19.9915,893,516.0005/12/2026 Filed 2026-05-14SCHEDULE 13D/AAmendment 5Open filing 0000902664-26-002450 Dispute this row
Avoro Ventures LLC Common stock, par value $0.0001 per share4.12,288,950.0005/12/2026 Filed 2026-05-14SCHEDULE 13D/AAmendment 5Open filing 0000902664-26-002450 Dispute this row
Behzad Aghazadeh Common stock, par value $0.0001 per share19.9918,292,675.0005/12/2026 Filed 2026-05-14SCHEDULE 13D/AAmendment 5Open filing 0000902664-26-002450 Dispute this row
Coastlands Capital LP Common stock5.982,819,215.0008/19/2025 Filed 2025-08-25SCHEDULE 13GOpen filing 0001172661-25-003766 Dispute this row
Coastlands Capital Partners LP Common stock5.982,819,215.0008/19/2025 Filed 2025-08-25SCHEDULE 13GOpen filing 0001172661-25-003766 Dispute this row
Coastlands Capital GP LLC Common stock5.982,819,215.0008/19/2025 Filed 2025-08-25SCHEDULE 13GOpen filing 0001172661-25-003766 Dispute this row
Coastlands Capital LLC Common stock5.982,819,215.0008/19/2025 Filed 2025-08-25SCHEDULE 13GOpen filing 0001172661-25-003766 Dispute this row
Matthew D. Perry Common stock5.982,819,215.0008/19/2025 Filed 2025-08-25SCHEDULE 13GOpen filing 0001172661-25-003766 Dispute this row
BML Investment Partners, L.P. Common stock, par value $0.0001 per share8.52,100,00012/31/2024 Filed 2024-12-31SCHEDULE 13DOpen filing 0001373604-24-000118 Dispute this row
Leonard Braden Michael Common stock, par value $0.0001 per share9.92,435,00012/31/2024 Filed 2024-12-31SCHEDULE 13DOpen filing 0001373604-24-000118 Dispute this row
AVORO CAPITAL ADVISORS LLC Common stock, par value $0.0001 per share11.62,849,402.0012/19/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 3Open filing 0000902664-24-007000 Dispute this row
AVORO VENTURES LLC Common stock, par value $0.0001 per share2.5622,350.0012/19/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 3Open filing 0000902664-24-007000 Dispute this row
BEHZAD AGHAZADEH Common stock, par value $0.0001 per share14.53,581,961.0012/19/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 3Open filing 0000902664-24-007000 Dispute this row
Neil Desai Common stock, par value $0.0001 per share9.22,263,56612/19/2024 Filed 2024-12-23SCHEDULE 13D/AAmendment 3Open filing 0000950170-24-139724 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,550,114 filings read, dated 2004-06-14 to 2026-11-18: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020176,407
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,403

Filings made before the SEC required XML are listed, not extracted.

Back to Whitehawk Therapeutics, Inc.